

**PHENDIMETRAZINE TARTRATE- phendimetrazine tartrate tablet**  
**PD-Rx Pharmaceuticals, Inc.**


-----  
**PHENDIMETRAZINE TARTRATE TABLETS, USP 35 mg, CIII**

**Rx Only**

**DESCRIPTION:**

Phendimetrazine tartrate, as the dextro isomer, has the chemical name of (2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)- tartrate (1:1).

The structural formula is:



$C_{12}H_{17}NO \cdot C_4H_6O_6$

M.W. 341.36

Phendimetrazine tartrate is a white, odorless crystalline powder. It is freely soluble in water; sparingly soluble in warm alcohol, insoluble in chloroform, acetone, ether and benzene.

Each white tablet, for oral administration, contains 35 mg of phendimetrazine tartrate. In addition, the following inactive ingredients are present: Colloidal Silicon Dioxide, Lactose Monohydrate, Microcrystalline Cellulose 102, Sodium Starch Glycolate and Stearic Acid. The yellow tablet also contains FD&C Yellow # 5 Aluminum Lake (15-17%). The blue tablet also contains FD&C Blue # 1 Aluminum Lake (11-13%).

**CLINICAL PHARMACOLOGY:**

Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics". It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system

actions or metabolic effects, may be involved for example.

Adult obese subjects instructed in dietary management and treated with anorectic drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short term clinical trials.

The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origin of the increased weight loss due to the various drug effects is not established. The amount of weight loss associated with the use of an anorectic drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

The major route of elimination is via the kidneys where most of the drug and metabolites are excreted. Some of the drug is metabolized to phendimetrazine and phendimetrazine-N-oxide. The average half-life of elimination when studied under controlled conditions is about 3.7 hours for both the extended-release and immediate release forms. The absorption half-life of the drug from the immediate release 35 mg phendimetrazine tablets is appreciably more rapid than the absorption rate of the drug from the extended-release formulation.

## **INDICATIONS AND USAGE:**

Phendimetrazine tartrate is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m<sup>2</sup> or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.

## BODY MASS INDEX (BMI) kg/m<sup>2</sup>

### Height (feet, inches)

Weight (pounds)	5'0"	5'3"	5'6"	5'9"	6'0"	6'3"
140	27	25	23	21	19	18
150	29	27	24	22	20	19
160	31	28	26	24	22	20
170	33	30	28	25	23	21
180	35	32	29	27	25	23
190	37	34	31	28	26	24
200	39	36	32	30	27	25
210	41	37	34	31	29	26
220	43	39	36	33	30	28
230	45	41	37	34	31	29
240	47	43	39	36	33	30
250	49	44	40	37	34	31

Phendimetrazine tartrate is indicated for use as monotherapy only.

### CONTRAINDICATIONS:

Known hypersensitivity or idiosyncratic reactions to sympathomimetics.

Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism, and glaucoma.

Highly nervous or agitated patients.

Patients with a history of drug abuse.

Patients taking other CNS stimulants, including monoamine oxidase inhibitors.

### WARNINGS:

**Phendimetrazine tartrate should not be used in combination with other anorectic agents, including prescribed drugs, over-the-counter preparations and herbal products.**

In a case-control epidemiological study, the use of anorectic agents, including phendimetrazine tartrate, was associated with an increased risk of developing pulmonary hypertension, a rare, but often fatal disorder. The use of anorectic agents for longer than three months was associated with a 23-fold increase in the risk of developing pulmonary hypertension. Increased risk of pulmonary hypertension with repeated courses of therapy cannot be excluded.

The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, phendimetrazine tartrate should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.

**Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other anorectic drugs. However, no cases of this valvulopathy have been reported when phendimetrazine tartrate has been used alone.**

The potential risk of possible serious adverse effects such as valvular heart disease and pulmonary hypertension should be assessed carefully against the potential benefit of weight loss. Baseline cardiac evaluation should be considered to detect pre-existing valvular heart diseases or pulmonary hypertension prior to initiation of phendimetrazine treatment. Phendimetrazine tartrate is not recommended in patients with known heart murmur or valvular heart disease. Echocardiogram during and after treatment could be useful for detecting any valvular disorders which may occur. To limit unwarranted exposure and risks, treatment with phendimetrazine tartrate should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (i.e., weight loss of at least 4 pounds, or as determined by the physician and patient).

Tolerance to the anorectic effect of phendimetrazine develops within a few weeks. When this occurs, its use should be discontinued; the maximum recommended dose should not be exceeded.

Use of phendimetrazine tartrate within 14 days following the administration of monoamine oxidase inhibitors may result in a hypertensive crisis.

Abrupt cessation of administration following prolonged high dosage results in extreme fatigue and depression. Because of the effect on the central nervous system, phendimetrazine tartrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.

Phendimetrazine tartrate is not recommended for patients who used any anorectic agents within the prior year.

## **PRECAUTIONS:**

Caution is to be exercised in prescribing phendimetrazine for patients with even mild hypertension.

Insulin requirements in diabetes mellitus may be altered in association with the use of phendimetrazine tartrate and the concomitant dietary regimen.

Phendimetrazine tartrate may decrease the hypotensive effect of guanethidine. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdose.

Only yellow tablet contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type

reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

### **Drug Interactions:**

Efficacy of phendimetrazine tartrate with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility:**

Studies with Phendimetrazine Tartrate have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

### ***Pregnancy: Pregnancy Category C:***

Animal reproduction studies have not been conducted with phendimetrazine tartrate. It is also not known whether phendimetrazine tartrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

### **Usage in Pregnancy:**

Safe use in pregnancy has not been established. Until more information is available, phendimetrazine tartrate should not be taken by women who are or may become pregnant unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.

### **Nursing Mothers:**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, phendimetrazine tartrate should not be taken by women who are nursing unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.

### **Pediatric Use:**

Safety and effectiveness in pediatric patients have not been established.

## **ADVERSE REACTIONS:**

**Cardiovascular:** Palpitations, tachycardia, elevated blood pressure, ischemic events.

Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine, both independently and especially when used in combination with other anorectic drugs, have been reported. However, no case of this valvulopathy has been reported when phendimetrazine tartrate has been used alone.

### **Central Nervous System:**

Overstimulation, restlessness, insomnia, agitation, flushing, tremor, sweating, dizziness, headache, psychotic state, blurring of vision.

### **Gastrointestinal:**

Dryness of the mouth, nausea, diarrhea, constipation, stomach pain.

**Genitourinary:**

Urinary frequency, dysuria, changes in libido.

**DRUG ABUSE AND DEPENDENCE:****Controlled Substance:**

Phendimetrazine tartrate tablets are a Schedule III controlled substance.

**Dependence:**

Phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phendimetrazine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.

**OVERDOSAGE:**

Acute overdosage with phendimetrazine tartrate may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerence, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma, and death.

The management of overdosage is largely symptomatic. It includes sedation with a barbiturate. If hypertension is marked, the use of a nitrate or rapid-acting alpha receptor-blocking agent should be considered. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations for its use.

**DOSAGE AND ADMINISTRATION:**

**Usual Adult Dosage:** 1 tablet (35 mg) twice a day or three times a day one hour before meals.

Dosage should be individualized to obtain an adequate response with the lowest effective dosage. In some cases, ½ tablet (17.5 mg) per dose may be adequate. Dosage should not exceed 2 tablets three times a day.

**HOW SUPPLIED:**

**Phendimetrazine Tartrate Tablets, USP 35 mg** are available as

Yellow, round, biconvex tablets debossed "K" above bisect "77" on one side and plain on the other side.

Bottles of 7 NDC 43063-510-07

Bottles of 14 NDC 43063-510-14

Bottles of 28 NDC 43063-510-28

Bottles of 30 NDC 43063-510-30

Bottles of 42 NDC 43063-510-42

Bottles of 56 NDC 43063-510-56

Bottles of 60 NDC 43063-510-60

Bottles of 135 NDC 43063-510-81

Bottles of 112 NDC 43063-510-88

Bottles of 90 NDC 43063-510-90

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

## Principal Display Panel

### Phendimetrazine Tartrate Tablets, USP

35 mg CIII

Rx Only

CAUTION: FEDERAL LAW PROHIBITS THE TRANSFER OF THIS DRUG TO ANY PERSON OTHER THAN TO WHOM IT WAS PRESCRIBED.

**R only** WARNING: KEEP THIS OUT OF THE REACH OF CHILDREN  
DOSAGE and STORAGE: SEE PACKAGE INSERT

43063-510-56	43063-510-56	43063-510-56
PHENDIMETRAZINE	PHENDIMETRAZINE	PHENDIMETRAZINE
TARTRATE USP	TARTRATE USP	TARTRATE USP
35 MG	35 MG	35 MG
56 TABLETS	56 TABLETS	56 TABLETS
ReOrder # 110321	ReOrder # 110321	ReOrder # 110321
LOT C23E03	LOT C23E03	LOT C23E03
EXP 04/2024	EXP 04/2024	EXP 04/2024

CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS.  
YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088

TAKE \_\_\_ TABLET(S) \_\_\_ TIMES A DAY.  
TOME \_\_\_ TABLETA(S) \_\_\_ VECES AL DIA.

Each TABLET Contains: PHENDIMETRAZINE  
TARTRATE USP 35 MG

NDC: 43063-510-56



PHENDIMETRAZINE  
TARTRATE USP

35 MG

56 TABLETS

YELLOW  
ORGANOLEPTIC MARKINGS:  
K 77  
RND/BISECTED



GTIN: 00343063510568  
SNO: C23E03000005  
EXP: 04/2024  
LOT: C23E03

43063510568  
1070200710  
KARTECH INC.  
NEWTON, PA 18940

**PHENDIMETRAZINE TARTRATE**

phendimetrazine tartrate tablet

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:43063-510(NDC:10702-077)
<b>Route of Administration</b>	ORAL	<b>DEA Schedule</b>	CIII

## Active Ingredient/Active Moiety

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
<b>PHENDIMETRAZINE TARTRATE</b> (UNII: 6985IP0T80) (PHENDIMETRAZINE - UNII:AB2794W8KV)	PHENDIMETRAZINE TARTRATE	35 mg

## Inactive Ingredients

<b>Ingredient Name</b>	<b>Strength</b>
<b>SILICON DIOXIDE</b> (UNII: ETJ7Z6XBU4)	
<b>FD&amp;C YELLOW NO. 5</b> (UNII: I753WB2F1M)	
<b>LACTOSE MONOHYDRATE</b> (UNII: EWQ57Q8I5X)	
<b>STEARIC ACID</b> (UNII: 4ELV7Z65AP)	
<b>CELLULOSE, MICROCRYSTALLINE</b> (UNII: OP1R32D61U)	
<b>SODIUM STARCH GLYCOLATE TYPE A POTATO</b> (UNII: 5856J3G2A2)	

## Product Characteristics

<b>Color</b>	yellow	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	7mm
<b>Flavor</b>		<b>Imprint Code</b>	K;77
<b>Contains</b>			

## Packaging

<b>#</b>	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:43063-510-07	7 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	06/23/2017	
2	NDC:43063-510-14	14 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	04/11/2017	
3	NDC:43063-510-28	28 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	09/15/2010	
4	NDC:43063-510-30	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	09/15/2010	
5	NDC:43063-510-56	56 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	06/23/2017	
6	NDC:43063-510-60	60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	09/15/2010	
7	NDC:43063-510-81	135 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	05/01/2018	
8	NDC:43063-510-88	112 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	04/19/2017	
9	NDC:43063-510-90	90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	04/19/2017	
10	NDC:43063-	42 in 1 BOTTLE, PLASTIC; Type 0: Not a	10/06/2022	



10	510-42	Combination Product	10/06/2023
----	--------	---------------------	------------

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA091042	09/15/2010	

**Labeler** - PD-Rx Pharmaceuticals, Inc. (156893695)

**Registrant** - PD-Rx Pharmaceuticals, Inc. (156893695)

## Establishment

Name	Address	ID/FEI	Business Operations
PD-Rx Pharmaceuticals, Inc.		156893695	repack(43063-510)

Revised: 10/2023

PD-Rx Pharmaceuticals, Inc.